search
Back to results

Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 (DIS-MVC)

Primary Purpose

HIV-1 Infection

Status
Unknown status
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Maraviroc
Sponsored by
Hospital Clinic of Barcelona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV-1 Infection focused on measuring HIV-1 infection, Maraviroc, CD4 lymphocyte count

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age or older
  • HIV infection
  • Patients receiving HAART treatment for at least one year with a sustained viral load equal or below 200 copies/ml
  • Viral load equal or below 200 copies/ml at the screening visit
  • Discordant patients: patients without an increment over 50 copies /ml of CD4 lymphocytes during the last year
  • Patients with an expected adherence to HIV treatment over 90% according to their physician.
  • Signed informed consent form

Exclusion Criteria:

  • Pregnancy or breast feeding or women planning pregnancy during the study duration
  • Any contraindication to treatment with Maraviroc
  • X4 tropism at inclusion

Sites / Locations

  • Hospital Clínic i Provincial

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Maraviroc

Control

Arm Description

Patients continue with their usual treatment

Outcomes

Primary Outcome Measures

Median of CD4 counts change after 24 weeks

Secondary Outcome Measures

Immunological profile
Immunohistochemistry and flow cytometry techniques will be performed on peripheral blood to study immunological response to Maraviroc treatment
CD4 counts
Number of pacients with CD4 counts over 200 cells/mm3
Clinical progression
Progression to diseases classified as category C in CDC HIV guidelines; to other diseases or patient death

Full Information

First Posted
November 4, 2010
Last Updated
November 18, 2010
Sponsor
Hospital Clinic of Barcelona
search

1. Study Identification

Unique Protocol Identification Number
NCT01235013
Brief Title
Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3
Acronym
DIS-MVC
Official Title
Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3
Study Type
Interventional

2. Study Status

Record Verification Date
October 2010
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Hospital Clinic of Barcelona

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Maraviroc is an antiretroviral drug that belongs to the family of the CCR5 coreceptor inhibitors. It has proven to be effective in increasing CD4 lymphocyte counts in both in treated and naïve patients, irrespective of the viral load. The investigators hypothesize that adding Maraviroc to the antiretroviral treatment of discordant patients, defined as those having CD4 lymphocyte counts below 200 cells /mm3 during the last year, could lead to its immunological recovery. 60 patients will be included in this unicentric, prospective, randomized and stratified clinical trial. They will be randomized to either continue with its usual high activity antiretroviral therapy (HAART) treatment or to receive 300 mg of Maraviroc every 12 hours plus its usual treatment. After 24 weeks, lymphocyte counts will be assessed, as well as safety, clinical progression, immunological profile of the patients and the potential benefit of Maraviroc for HIV+ cirrhotic patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV-1 Infection
Keywords
HIV-1 infection, Maraviroc, CD4 lymphocyte count

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Maraviroc
Arm Type
Experimental
Arm Title
Control
Arm Type
No Intervention
Arm Description
Patients continue with their usual treatment
Intervention Type
Drug
Intervention Name(s)
Maraviroc
Intervention Description
150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
Primary Outcome Measure Information:
Title
Median of CD4 counts change after 24 weeks
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Immunological profile
Description
Immunohistochemistry and flow cytometry techniques will be performed on peripheral blood to study immunological response to Maraviroc treatment
Time Frame
24 weeks
Title
CD4 counts
Description
Number of pacients with CD4 counts over 200 cells/mm3
Time Frame
24 weeks
Title
Clinical progression
Description
Progression to diseases classified as category C in CDC HIV guidelines; to other diseases or patient death
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age or older HIV infection Patients receiving HAART treatment for at least one year with a sustained viral load equal or below 200 copies/ml Viral load equal or below 200 copies/ml at the screening visit Discordant patients: patients without an increment over 50 copies /ml of CD4 lymphocytes during the last year Patients with an expected adherence to HIV treatment over 90% according to their physician. Signed informed consent form Exclusion Criteria: Pregnancy or breast feeding or women planning pregnancy during the study duration Any contraindication to treatment with Maraviroc X4 tropism at inclusion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
José María Gatell, MD
Phone
0034932275400
Email
jmgatell@clinic.ub.es
First Name & Middle Initial & Last Name or Official Title & Degree
Judit Pich, Pharmacist
Phone
0034932275400
Email
jpich@clinic.ub.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
José Luis Blanco, MD
Organizational Affiliation
Hospital Clínic i Provincial
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Clínic i Provincial
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
José María Gatell, MD
Phone
0034932275400
Email
jmgatell@clinic.ub.es
First Name & Middle Initial & Last Name & Degree
Judit Pich, Pharmacist
Phone
0034932275400
Email
jpich@clinic.ub.es
First Name & Middle Initial & Last Name & Degree
José Luis Blanco, MD

12. IPD Sharing Statement

Learn more about this trial

Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3

We'll reach out to this number within 24 hrs